The incidence of male urethral cancer is rare with age preponderance of 50 to 60 years. The standard management approach is surgery.
Here, we present a novel treatment approach for male urethral cancer.
Thirty-six year old male, case of primary clear cell adenocarcinoma of urethra who refused surgery, underwent cystoscopic assisted intraluminal HDR brachytherapy. Patient received a dose of 36 Gy in 9 fractions (4 Gy per fraction) followed by a boost of 24 Gy in 6 fractions.
At 11 months post treatment, disease is well controlled with no post treatment toxicity so far. Intraluminal brachytherapy seems to be an effective novel treatment for male urethral cancer.
J Contemp Brachytherapy. 2015 Jun;7(3):248-51. doi: 10.5114/jcb.2015.52316. Epub 2015 Jun 15.
Lewis S1, Pal M2, Bakshi G2, Ghadi YG3, Menon S4, Murthy V1, Mahantshetty U1.
1 Department of Radiation Oncology.
2 Department of Surgical Oncology.
3 Department of Radiation Physics.
4 Department of Pathology, Tata Memorial Centre, Parel, Mumbai, India.